{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T22:07:46Z","timestamp":1781302066254,"version":"3.54.1"},"reference-count":105,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2020,12,14]],"date-time":"2020-12-14T00:00:00Z","timestamp":1607904000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Classic Hodgkin lymphoma (cHL) is a unique lymphoid neoplasm characterized by extensive immune infiltrates surrounding rare malignant Hodgkin Reed\u2013Sternberg (HRS) cells. Different subsets of T and NK cells have long been recognized in the cHL microenvironment, yet their distinct contribution to disease pathogenesis has remained enigmatic. Very recently, novel platforms for high dimensional analysis of immune cells, such as single-cell RNA sequencing and mass cytometry, have revealed unanticipated insights into the composition of T- and NK-cell compartments in cHL. Advances in imaging techniques have better defined specific T-helper subpopulations physically interacting with neoplastic cells. In addition, the identification of novel cytotoxic subsets with an exhausted phenotype, typically enriched in cHL milieu, is shedding light on previously unrecognized immune evasion mechanisms. This review examines the immunological features and the functional properties of T and NK subsets recently identified in the cHL microenvironment, highlighting their pathological interplay with HRS cells. We also discuss how this knowledge can be exploited to predict response to immunotherapy and to design novel strategies to improve PD-1 blockade efficacy.<\/jats:p>","DOI":"10.3390\/cancers12123757","type":"journal-article","created":{"date-parts":[[2020,12,14]],"date-time":"2020-12-14T21:25:08Z","timestamp":1607981108000},"page":"3757","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["The Evolving Knowledge on T and NK Cells in Classic Hodgkin Lymphoma: Insights into Novel Subsets Populating the Immune Microenvironment"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9867-8335","authenticated-orcid":false,"given":"Isacco","family":"Ferrarini","sequence":"first","affiliation":[{"name":"Section of Hematology, Department of Medicine, University of Verona, 37134 Verona, Italy"},{"name":"Cancer Research and Cell Biology Laboratory, Department of Medicine, University of Verona, 37134 Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Rigo","sequence":"additional","affiliation":[{"name":"Section of Hematology, Department of Medicine, University of Verona, 37134 Verona, Italy"},{"name":"Cancer Research and Cell Biology Laboratory, Department of Medicine, University of Verona, 37134 Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2863-0883","authenticated-orcid":false,"given":"Carlo","family":"Visco","sequence":"additional","affiliation":[{"name":"Section of Hematology, Department of Medicine, University of Verona, 37134 Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7280-2040","authenticated-orcid":false,"given":"Mauro","family":"Krampera","sequence":"additional","affiliation":[{"name":"Section of Hematology, Department of Medicine, University of Verona, 37134 Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3855-6747","authenticated-orcid":false,"given":"Fabrizio","family":"Vinante","sequence":"additional","affiliation":[{"name":"Section of Hematology, Department of Medicine, University of Verona, 37134 Verona, Italy"},{"name":"Cancer Research and Cell Biology Laboratory, Department of Medicine, University of Verona, 37134 Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,12,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41572-020-0189-6","article-title":"Hodgkin lymphoma","volume":"6","author":"Connors","year":"2020","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1177\/095952873201700106","article-title":"On some morbid appearances of the absorbent glands and spleen","volume":"17","author":"Hodgkin","year":"1832","journal-title":"Med. Chir. Trans."},{"key":"ref_3","first-page":"133","article-title":"On the pathological changes in Hodgkin\u2019s disease with special reference to its relation to tuberculosis","volume":"10","author":"Reed","year":"1902","journal-title":"John Hopkins Hosp. Rep."},{"key":"ref_4","first-page":"21","article-title":"\u00dcber eine eigenartige unter dem Bilde der Pseudoleuk\u00e4mie verlaufende Tuberkolose des lymphatischen Apparates","volume":"19","author":"Sternberg","year":"1898","journal-title":"Z. Heilkd."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Calabretta, E., d\u2019Amore, F., and Carlo-Stella, C. (2019). Immune and Inflammatory Cells of the Tumor Microenvironment Represent Novel Therapeutic Targets in Classical Hodgkin Lymphoma. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20215503"},{"key":"ref_6","first-page":"351","article-title":"The Nature of the Lymphocytes Surrounding Reed-Sternberg Cells in Nodular Lymphocyte Predominance and in Other Types of Hodgkin\u2019s Disease","volume":"135","author":"Poppema","year":"1989","journal-title":"Am. J. Pathol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1093\/annonc\/9.suppl_5.S21","article-title":"Immune escape mechanisms in Hodgkin\u2019s disease","volume":"9","author":"Poppema","year":"1998","journal-title":"Ann. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1006\/scbi.2000.0327","article-title":"Interaction between host T cells and Reed\u2013Sternberg cells in Hodgkin lymphomas","volume":"10","author":"Poppema","year":"2000","journal-title":"Semin. Cancer Biol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"4283","DOI":"10.1182\/blood-2002-01-0099","article-title":"The role of cytokines in classical Hodgkin lymphoma","volume":"99","author":"Skinnider","year":"2002","journal-title":"Blood"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2856","DOI":"10.1182\/blood-2013-06-508044","article-title":"Defining characteristics of classical Hodgkin lymphoma microenvironment T-helper cells","volume":"122","author":"Greaves","year":"2013","journal-title":"Blood"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1182\/blood-2003-07-2594","article-title":"Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma","volume":"103","author":"Marshall","year":"2004","journal-title":"Blood"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"415","DOI":"10.3389\/fonc.2019.00415","article-title":"Validation of CyTOF Against Flow Cytometry for Immunological Studies and Monitoring of Human Cancer Clinical Trials","volume":"9","author":"Gadalla","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1002\/JLB.6MR0320-234R","article-title":"Unravelling the heterogeneity and dynamic relationships of tumor-infiltrating T cells by single-cell RNA sequencing analysis","volume":"107","author":"Yu","year":"2020","journal-title":"J. Leuk. Biol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s13045-018-0637-x","article-title":"Immune cell subset differentiation and tissue inflammation","volume":"11","author":"Fang","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.cmet.2017.06.016","article-title":"Metabolic Regulation of T Cell Longevity and Function in Tumor Immunotherapy","volume":"26","author":"Kishton","year":"2017","journal-title":"Cell Metab."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/imr.12037","article-title":"Helper T-cell identity and evolution of differential transcriptomes and epigenomes","volume":"252","author":"Vahedi","year":"2013","journal-title":"Immunol. Rev."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1146\/annurev-immunol-030409-101212","article-title":"Differentiation of effector CD4 T cell populations","volume":"28","author":"Zhu","year":"2010","journal-title":"Annu. Rev. Immunol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.coi.2011.08.007","article-title":"The many faces of Th17 cells","volume":"23","author":"Peters","year":"2011","journal-title":"Curr. Opin. Immunol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1196\/annals.1375.031","article-title":"Upregulation of Foxp3 Expression in Mouse and Human Treg Is IL-2\/STAT5 Dependent: Implications for the NOD STAT5B Mutation in Diabetes Pathogenesis","volume":"1079","author":"Murawski","year":"2006","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1182\/blood-2018-04-843714","article-title":"Mass cytometry of Hodgkin lymphoma reveals a CD4+ regulatory T-cell-rich and exhausted T-effector microenvironment","volume":"132","author":"Cader","year":"2018","journal-title":"Blood"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3983","DOI":"10.1182\/blood.V84.11.3983b.bloodjournal84113983b","article-title":"CD30 Antigen and Cellular Biology of Reed-Sternberg Cells","volume":"84","author":"Pizzolo","year":"1994","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1002\/ijc.23119","article-title":"Expression of CCR5 receptors on Reed\u2013Sternberg cells and Hodgkin lymphoma cell lines: Involvement of CCL5\/Rantes in tumor cell growth and microenvironmental interactions","volume":"122","author":"Aldinucci","year":"2008","journal-title":"Int. J. Cancer"},{"key":"ref_23","first-page":"2788","article-title":"Human CD8+ HLA-DR+ Regulatory T Cells, Similarly to Classical CD4+FoxP3+ cells suppress Immune Responses via PD-1\/PD-L1 Axis","volume":"9","author":"Machicote","year":"2018","journal-title":"Front. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"564","DOI":"10.3324\/haematol.2018.196725","article-title":"CCR5 antagonism by maraviroc inhibits Hodgkin lymphoma microenvironment interactions and xenograft growth","volume":"104","author":"Casagrande","year":"2019","journal-title":"Haematologica"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1182\/blood.V94.6.2065","article-title":"Hodgkin\/Reed-Sternberg Cells Induce Fibroblasts to Secrete Eotaxin, a Potent Chemoattractant for T Cells and Eosinophils","volume":"94","author":"Jundt","year":"1999","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"5747","DOI":"10.4049\/jimmunol.1203542","article-title":"Different GATA Factors Dictate CCR3 Transcription in Allergic Inflammatory Cells in a Cell Type-Specific Manner","volume":"190","author":"Kong","year":"2013","journal-title":"J. Immunol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0002-9440(10)65424-7","article-title":"High Expression of the CC Chemokine TARC in Reed-Sternberg Cells. A possible explanation for the characteristic T-cell infiltratein Hodgkin\u2019s lymphoma","volume":"154","author":"Visser","year":"1999","journal-title":"Am. J. Pathol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/j.1365-2141.2007.06964.x","article-title":"Serum chemokine levels in Hodgkin lymphoma patients: Highly increased levels of CCL17 and CCL22","volume":"140","author":"Niens","year":"2008","journal-title":"Br. J. Haematol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1200\/JCO.2013.52.0924","article-title":"Multicenter Phase II Study of Mogamulizumab (KW-0761), a Defucosylated Anti-CC Chemokine Receptor 4 Antibody, in Patients with Relapsed Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma","volume":"32","author":"Ogura","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.1182\/blood-2008-01-134783","article-title":"Aberrant expression of the Th2 cytokine IL-21 in Hodgkin lymphoma cells regulates STAT3 signaling and attracts T reg cells via regulation of MIP-3alpha","volume":"112","author":"Lamprecht","year":"2008","journal-title":"Blood"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"3395","DOI":"10.1080\/10428194.2019.1636983","article-title":"Classical Hodgkin lymphoma cells may promote an IL-17-enriched microenvironment","volume":"60","author":"Ferrarini","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"195","DOI":"10.2353\/ajpath.2008.070845","article-title":"Expression of the Epstein-Barr Virus-Encoded Epstein-Barr Virus Nuclear Antigen 1 in Hodgkin\u2019s Lymphoma Cells Mediates Up-Regulation of CCL20 and the Migration of Regulatory T Cells","volume":"173","author":"Baumforth","year":"2008","journal-title":"Am. J. Pathol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.virol.2016.10.015","article-title":"Epstein-Barr Virus Latent Membrane Protein 2A (LMP2A) enhances IL-10 production through the activation of Bruton\u2019s tyrosine kinase and STAT3","volume":"500","author":"Incrocci","year":"2017","journal-title":"Virology"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.immuni.2014.06.008","article-title":"Macrophage Activation and Polarization: Nomenclature and Experimental Guidelines","volume":"41","author":"Murray","year":"2014","journal-title":"Immunity"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1023\/A:1008301602785","article-title":"Interleukin-10 levels are often elevated in serum of adults with Hodgkin\u2019s disease and are associated with inferior failure-free survival","volume":"10","author":"Sarris","year":"1999","journal-title":"Ann. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1080\/10428190410001712234","article-title":"Elevated Serum Levels of IL-10 are Associated with Inferior Progression-Free Survival in Patients with Hodgkin\u2019s Disease Treated with Radiotherapy","volume":"45","author":"Visco","year":"2004","journal-title":"Leuk. Lymphoma"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s00262-008-0528-z","article-title":"Expression and function of T cell homing molecules in Hodgkin\u2019s lymphoma","volume":"58","author":"Machado","year":"2009","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1182\/blood-2014-05-576140","article-title":"Reed-Sternberg cell-derived lymphotoxin-a activates endothelial cells to enhance T-cell recruitment in classical Hodgkin lymphoma","volume":"124","author":"Fhu","year":"2014","journal-title":"Blood"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Aldinucci, D., Borghese, C., and Casagrande, N. (2019). Formation of the Immunosuppressive Microenvironment of Classic Hodgkin Lymphoma and Therapeutic Approaches to Counter It. Int. J. Mol. Sci., 20.","DOI":"10.20944\/preprints201904.0209.v1"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/nature22360","article-title":"Stability and function of regulatory T cells expressing the transcription factor T-bet","volume":"546","author":"Levine","year":"2017","journal-title":"Nature"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1158\/2326-6066.CIR-17-0325","article-title":"Complex Immune Evasion Strategies in Classical Hodgkin Lymphoma","volume":"5","author":"Wein","year":"2017","journal-title":"Cancer Immunol. Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/hon.878","article-title":"Prognostic impact of tumour-infiltrating Th2 and regulatory T cells in classical Hodgkin lymphoma","volume":"27","author":"Schreck","year":"2009","journal-title":"Hematol. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1182\/bloodadvances.2017007260","article-title":"Th17 immune microenvironment in Epstein-Barr virus-negative Hodgkin lymphoma: Implications for immunotherapy","volume":"1","author":"Duffield","year":"2017","journal-title":"Blood Adv."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1158\/2159-8290.CD-19-0680","article-title":"Single-Cell Transcriptome Analysis Reveals Disease-Defining T-cell Subsets in the Tumor Microenvironment of Classic Hodgkin Lymphoma","volume":"10","author":"Aoki","year":"2020","journal-title":"Cancer Discov."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1007\/s00262-020-02591-y","article-title":"Aberrant peripheral blood CD4+CD25+FOXP3+ regulatory T cells\/T helper-17 number is associated with the outcome of patients with lymphoma","volume":"69","author":"Dehghani","year":"2020","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_46","first-page":"282","article-title":"Serum levels of soluble CD30 molecule (Ki-1 antigen) in Hodgkin\u2019s disease: Relationship with disease activity and clinical stage","volume":"75","author":"Pizzolo","year":"1990","journal-title":"Br. J. Haematol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.semcancer.2013.07.002","article-title":"The microenvironment in classical Hodgkin lymphoma: An actively shaped and essential tumor component","volume":"24","author":"Liu","year":"2014","journal-title":"Semin. Cancer Biol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"4706","DOI":"10.1182\/blood-2007-08-105643","article-title":"IL-21 is expressed in Hodgkin lymphoma and activates STAT5: Evidence that activated STAT5 is required for Hodgkin lymphomagenesis","volume":"111","author":"Scheeren","year":"2008","journal-title":"Blood"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"3884","DOI":"10.4049\/jimmunol.0802246","article-title":"IL-17 Induces Monocyte Migration in Rheumatoid Arthritis","volume":"182","author":"Shahrara","year":"2009","journal-title":"J. Immunol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1182\/blood-2008-07-168096","article-title":"Molecular profiling of classical Hodgkin lymphoma tissues uncovers variations in the tumor microenvironment and correlations with EBV infection and outcome","volume":"113","author":"Chetaille","year":"2009","journal-title":"Blood"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/cmi.2015.44","article-title":"Type 1 regulatory T cells: A new mechanism of peripheral immune tolerance","volume":"12","author":"Zeng","year":"2015","journal-title":"Cell Mol. Immunol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1111\/bjh.12980","article-title":"Epstein-Barr virus infection induces an increase of T regulatory type 1 cells in Hodgkin lymphoma patients","volume":"166","author":"Morales","year":"2014","journal-title":"Br. J. Haematol."},{"key":"ref_53","first-page":"99","article-title":"CTLA-4, an Essential Immune-Checkpoint for T-Cell Activation","volume":"410","author":"Chikuma","year":"2017","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"ref_54","first-page":"2059","article-title":"The microenvironmental niche in classic Hodgkin lymphoma is enriched for CTLA-4-positive T cells that are PD-1-negative","volume":"134","author":"Patel","year":"2019","journal-title":"Blood"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1182\/blood-2017-06-781989","article-title":"Signaling pathways and immune evasion mechanisms in classical Hodgkin lymphoma","volume":"130","author":"Liu","year":"2017","journal-title":"Blood"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/cei.12716","article-title":"The impact of HLA class I and EBV latency-II antigen-specific CD8(+) T cells on the pathogenesis of EBV(+) Hodgkin lymphoma","volume":"183","author":"Jones","year":"2016","journal-title":"Clin. Exp. Immunol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1182\/blood-2006-04-015164","article-title":"Expression of LAG-3 by tumor-infiltrating lymphocytes is coincident with the suppression of latent membrane antigen-specific CD8+ T-cell function in Hodgkin lymphoma patients","volume":"108","author":"Gandhi","year":"2006","journal-title":"Blood"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/s41568-019-0235-4","article-title":"CD8+ T cell states in human cancer: Insights from single-cell analysis","volume":"20","author":"Thommen","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1182\/bloodadvances.2018017244","article-title":"CXCR5 and ICOS expression identifies a CD8 T-cell subset with TFH features in Hodgkin lymphomas","volume":"2","author":"Le","year":"2018","journal-title":"Blood Adv."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1158\/0008-5472.CAN-17-1987","article-title":"Germinal Centers Determine the Prognostic Relevance of Tertiary Lymphoid Structures and Are Impaired by Corticosteroids in Lung Squamous Cell Carcinoma","volume":"78","author":"Silina","year":"2018","journal-title":"Cancer Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1182\/blood-2007-01-066100","article-title":"Galectin-1 mediated suppression of Epstein-Barr virus-specific T-cell immunity in classic Hodgkin lymphoma","volume":"110","author":"Gandhi","year":"2007","journal-title":"Blood"},{"key":"ref_62","first-page":"1","article-title":"Putting the natural killer cell in its place","volume":"117","author":"Hart","year":"2005","journal-title":"Immunology"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1182\/blood-2014-11-610436","article-title":"Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cells","volume":"125","author":"Reichel","year":"2015","journal-title":"Blood"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3389\/fimmu.2018.00267","article-title":"Acquired Natural Killer Cell Dysfunction in the Tumor Microenvironment of Classic Hodgkin Lymphoma","volume":"9","author":"Chiu","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"5260","DOI":"10.4049\/jimmunol.170.10.5260","article-title":"Different Modes of IL-10 and TGF-\u03b2 to Inhibit Cytokine-Dependent IFN-\u03b3 Production: Consequences for Reversal of Lipopolysaccharide Desensitization","volume":"170","author":"Meisel","year":"2003","journal-title":"J. Immunol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bjc.1995.354","article-title":"Increased soluble interleukin-2 receptor concentration in plasma predicts a decreased cellular response to IL-2","volume":"72","author":"Gooding","year":"1995","journal-title":"Br. J. Cancer."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1006\/cyto.1996.0181","article-title":"Regulation of Fas and Fas-ligand expression in NK cells by cytokines and the involvement of Fas-ligand in NK\/LAK cell-mediated cytotoxicity","volume":"9","author":"Medvedev","year":"1997","journal-title":"Cytokine"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1182\/blood-2017-03-770719","article-title":"Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma","volume":"130","author":"Carey","year":"2017","journal-title":"Blood"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S1471-4906(01)02060-9","article-title":"The biology of human natural killer-cell subsets","volume":"22","author":"Cooper","year":"2001","journal-title":"Trends Immunol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2017-07-796342","article-title":"Immune evasion via PD-1\/PD-L1 on NK cells and monocyte\/macrophages is more prominent in Hodgkin lymphoma than DLBCL","volume":"131","author":"Vari","year":"2018","journal-title":"Blood"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1182\/bloodadvances.2018030676","article-title":"Human peripheral blood DNAM-1 neg NK cells are a terminally differentiated subset with limited effector functions","volume":"3","author":"Stannard","year":"2019","journal-title":"Blood Adv."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"112714","DOI":"10.1016\/j.jim.2019.112714","article-title":"Multiplex immunofluorescence staining and image analysis assay for diffuse large B cell lymphoma","volume":"478","author":"Lee","year":"2020","journal-title":"J. Immunol. Methods"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.3389\/fimmu.2019.02657","article-title":"Mass Cytometry Imaging for the Study of Human Diseases-Applications and Data Analysis Strategies","volume":"10","author":"Baharlou","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Reinke, S., Br\u00f6ckelmann, P.J., Iaccarino, I., Garcia-Marquez, M.A., Borchmann, S., Jochims, F., Kotrova, M., Pal, K., Br\u00fcggemann, M., and Hartmann, E. (2020). Tumor and microenvironment response but no cytotoxic T-cell activation in classic Hodgkin lymphoma treated with anti-PD1. Blood.","DOI":"10.1182\/blood.2020008553"},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Veldman, J., Visser, L., Huberts-Kregel, M., Muller, N., Hepkema, B., Van den Berg, A., and Diepstra, A. (2020). Rosetting T cells in Hodgkin lymphoma are activated by immunological synapse components HLA class II and CD58. Blood.","DOI":"10.1182\/blood.2020005546"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1056\/NEJMra1514296","article-title":"Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway","volume":"375","author":"Boussiotis","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.immuni.2004.06.017","article-title":"B7-1 and B7-2 Selectively Recruit CTLA-4 and CD28 to the Immunological Synapse","volume":"21","author":"Egen","year":"2004","journal-title":"Immunity"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"176","DOI":"10.18632\/genesandcancer.180","article-title":"The promising immune checkpoint LAG-3: From tumor microenvironment to cancer immunotherapy","volume":"9","author":"Long","year":"2018","journal-title":"Genes Cancer"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41408-019-0185-9","article-title":"Reverse signaling via PD-L1 supports malignant cell growth and survival in classical Hodgkin lymphoma","volume":"9","author":"Jalali","year":"2019","journal-title":"Blood Cancer J."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin\u2019s Lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1200\/JCO.2016.67.3467","article-title":"Programmed Death-1 Blockade with Pembrolizumab in Patients with Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure","volume":"34","author":"Armand","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1200\/JCO.2017.76.0793","article-title":"Nivolumab for Relapsed\/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial","volume":"36","author":"Armand","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1182\/blood.2019000324","article-title":"Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087","volume":"134","author":"Chen","year":"2019","journal-title":"Blood"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1200\/JCO.2017.77.3994","article-title":"Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma","volume":"36","author":"Roemer","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"e46","DOI":"10.1038\/bcj.2011.46","article-title":"The JAK inhibitor AZD1480 regulates proliferation and immunity in Hodgkin lymphoma","volume":"1","author":"Derenzini","year":"2011","journal-title":"Blood Cancer J."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"4069","DOI":"10.1182\/bloodadvances.2020002098","article-title":"The critical role of CD4+ T cells in PD-1 blockade against MHC-II\u2013expressing tumors such as classic Hodgkin lymphoma","volume":"4","author":"Nagasaki","year":"2020","journal-title":"Blood Adv."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1038\/s41591-020-1006-1","article-title":"A peripheral immune signature of responsiveness to PD-1 blockade in patients with classical Hodgkin lymphoma","volume":"26","author":"Cader","year":"2020","journal-title":"Nat. Med."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1182\/blood.2019000847","article-title":"The immune landscape and response to immune checkpoint blockade therapy in lymphoma","volume":"135","author":"Kline","year":"2020","journal-title":"Blood"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"10501","DOI":"10.1038\/ncomms10501","article-title":"Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints","volume":"7","author":"Koyama","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1126\/science.aaf2807","article-title":"Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade","volume":"354","author":"Pauken","year":"2016","journal-title":"Science"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.cell.2017.06.007","article-title":"De Novo Epigenetic Programs Inhibit PD-1 Blockade-Mediated T Cell Rejuvenation","volume":"170","author":"Ghoneim","year":"2017","journal-title":"Cell"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1200\/JCO.18.02151","article-title":"Addition of Low-Dose Decitabine to Anti-PD-1 Antibody Camrelizumab in Relapsed\/Refractory Classical Hodgkin Lymphoma","volume":"37","author":"Nie","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Armand, P., Lesokhin, A., Borrello, I., Timmerman, J., Gutierrez, M., Zhu, L., Popa McKiver, M., and Ansell, S.M. (2020). A phase 1b study of dual PD-1 and CTLA-4 or KIR blockade in patients with relapsed\/refractory lymphoid malignancies. Leukemia.","DOI":"10.1038\/s41375-020-0939-1"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"eaar3342","DOI":"10.1126\/scitranslmed.aar3342","article-title":"MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma","volume":"10","author":"Rodig","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1158\/1535-7163.MCT-18-1376","article-title":"Preclinical Development of the Anti-LAG-3 Antibody REGN3767: Characterization and Activity in Combination with the Anti-PD-1 Antibody Cemiplimab in Human PD-1xLAG-3-Knockin Mice","volume":"18","author":"Burova","year":"2019","journal-title":"Mol. Cancer Ther."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1080\/19420862.2019.1629239","article-title":"Characterization of a novel anti-human lymphocyte activation gene 3 (LAG-3) antibody for cancer immunotherapy","volume":"11","author":"Yu","year":"2019","journal-title":"MAbs"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"9520","DOI":"10.1200\/JCO.2017.35.15_suppl.9520","article-title":"Initial efficacy of anti-lymphocyte activation gene-3 (anti\u2013LAG-3; BMS-986016) in combination with nivolumab (nivo) in pts with melanoma (MEL) previously treated with anti\u2013PD-1\/PD-L1 therapy","volume":"35","author":"Ascierto","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"4024","DOI":"10.1182\/blood-2014-12-614636","article-title":"A phase 1 study of the bispecific anti-CD30\/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma","volume":"125","author":"Rothe","year":"2015","journal-title":"Blood"},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Bartlett, N.L., Herrera, A.F., Domingo-Domenech, E., Mehta, A., Forero-Torres, A., Garcia-Sanz, R., Armand, P., Devata, S., Rodriguez Izquierdo, A., and Lossos, I.S. (2020). A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma. Blood.","DOI":"10.1182\/blood.2019004701"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"13045","DOI":"10.1073\/pnas.1516107112","article-title":"90Y-daclizumab, an anti-CD25 monoclonal antibody, provided responses in 50% of patients with relapsed Hodgkin\u2019s lymphoma","volume":"112","author":"Janik","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1182\/blood-2018-99-118198","article-title":"Phase 1 Study of Adct-301 (Camidanlumab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody Drug Conjugate, in Relapsed\/Refractory Classical Hodgkin Lymphoma","volume":"132","author":"Hamadani","year":"2018","journal-title":"Blood"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1080\/10428194.2017.1387908","article-title":"Phase I dose escalation study of the anti-CD2 monoclonal antibody, siplizumab, with DA-EPOCH- R in aggressive peripheral T-cell lymphomas","volume":"59","author":"Roswarski","year":"2018","journal-title":"Leuk. Lymphoma"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"e660","DOI":"10.1016\/S2352-3026(20)30221-0","article-title":"Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: Phase 1 results of an open-label, multicentre, phase 1\/2 trial","volume":"7","author":"Diefenbach","year":"2020","journal-title":"Lancet Haematol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1002\/path.4306","article-title":"Protrusion-guided extracellular vesicles mediate CD30 trans-signalling in the microenvironment of Hodgkin\u2019s lymphoma","volume":"232","author":"Hansen","year":"2014","journal-title":"J. Pathol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1200\/JCO.20.01342","article-title":"Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma","volume":"38","author":"Ramos","year":"2020","journal-title":"J. Clin. Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/12\/3757\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:44:43Z","timestamp":1760179483000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/12\/3757"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,14]]},"references-count":105,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["cancers12123757"],"URL":"https:\/\/doi.org\/10.3390\/cancers12123757","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,14]]}}}